ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO201

Effectiveness of Sucroferric Oxyhydroxide in Phosphate Binder-Naïve and -Experienced Patients: A Real-World Retrospective Database Analysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Chazot, Charles, NephroCare France, Fresnes, France
  • Ramos, Rosa, NephroCare Spain, Madrid, Spain
  • Di Benedetto, Attilio, NephroCare Italy, Naples, Italy
  • Ferreira, Manuel A., Nova Medical School, Lisbon, Portugal
  • Kagermeier, Birgit, Fresenius Medical Care, Bad Homburg, Germany
  • Arens, Hans-Juergen, Fresenius Medical Care, Bad Homburg, Germany
  • Walpen, Sebastian, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland
  • Rakov, Viatcheslav, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland
  • Stuard, Stefano, Fresenius Medical Care, Bad Homburg, Germany

Retrospective analysis of a clinical database (EuCliD5) assessed the real-world effectiveness of an iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), to control serum phosphorus (sP) levels in hemodialysis (HD) patients (pts) in European countries.


De-identified data were extracted from electronic records for adult HD pts in 4 countries (France, Italy, Spain, Portugal) who were newly prescribed SFOH as part of routine care between Jan 2016 and Oct 2017. Baseline (BL) was defined as the 3-month period prior to SFOH prescription. Mean PB pill burden and sP levels were analyzed for Months 1–3 (Q1) and Months 4–6 (Q2) of SFOH treatment using mean values from the BL period as the reference. Effectiveness of SFOH for control of sP levels was evaluated for pts who had not received PB therapy during BL (PB-naïve) and those who had (PB-experienced).


1347 pts were included (mean age: 61.6 years; 63.5% male), of whom 605 pts were PB-experienced and 742 were PB-naïve. Characteristics of pts in these subgroups were generally comparable; median dialysis vintage was longer in PB-experienced vs. -naïve pts (50 vs. 34 months). The % of pts with sP control (≤5.5 mg/dL) during BL was lower in the PB-experienced (31.6%) vs. the PB-naïve (44.9%) subgroup (Figure). In both subgroups, the % pts achieving sP ≤5.5 mg/dL increased significantly from BL through Q1 and Q2. For PB-experienced pts, these sP improvements were achieved with a reduction in PB pill burden.


In routine practice, SFOH therapy improved sP control in both PB-naïve and PB-experienced HD pts, with a relatively low daily pill burden.


  • Commercial Support